Social Media Should be used as a Diverse and Cost Effective Data Source of Patient Reported Outcomes (PRO)

A recent paper published in Value in Health comments on how social platforms could accelerate PRO development

Philadelphia, PA, March 6, 2015

Written by a team of nonprofit, private industry and government officials and published in Value in Health, the paper compares various approaches to collecting and analyzing patient reported outcomes (PROs) and outlines a vision of how social platforms should be included as sources of data collection.

More specifically the authors of the paper aim to answer questions about how different patient populations are represented on social media, how they should be targeted, and which channels of social media are most appropriate for PRO.

As more patients share their health experiences online, the internet has become a vast database for developing and validating new PROs because researchers can more easily target and engage patient populations online than with traditional methods such as face-to-face or telephone interviews.

The authors address an issue that has, until now, received little attention in the scientific literature: how to collect data that supports content validity in a way that is acceptable for regulatory use in pharmaceutical labeling.

---

Article details
“Can We Use Social Media to Support Content Validity of Patient Reported PRO Instruments in Medical Product Development?” (doi:10.1016/j.jval.2014.10.001) Value in Health, published by Elsevier.

Author details
Ari Gnanaskathy, Head of Patient Reported Outcomes at RTI Health Solutions; Elektra J. Papadopoulos, MD, MPH; Study Endpoints and Labeling Development (SEALD); Study Endpoints team in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA); Margaret Rothman, PhD, CEO, Rothman Associates Consulting; and Paul Wicks, PhD, Vice President of Innovation at PatientsLikeMe.

Full text of this open access article is available at: http://www.valueinhealthjournal.com/article/S1098-3015(14)04726-3/fulltext

http://www.sciencedirect.com/science/article/pii/S1098301514047263

Journalists wishing to interview the authors can contact: Terry Materese, Executive Publisher Elsevier: t.materese@elsevier.com | at +1 215 239 3196.

About Value in Health
Value in Health, publishes original research articles in the areas of pharmacoeconomics (health economics), outcomes research (clinical, economic, and patient-reported outcomes research), and conceptual and health policy articles that are rigorous, methodologically or theoretically solid, ethically sound and provide valuable information for health care decision-makers as well as the research community. As the official journal of ISPOR, Value in Health provides a forum for researchers, as well as health care decision-makers to translate outcomes research into health care decisions. Value in Health can be accessed at the journal’s website: http://www.valueinhealthjournal.com

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Media Contact
Terry Materese
Elsevier
+1 215 239 3196
t.materese@elsevier.com